MAPK

[Scientific Reports] Researchers evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and mitogen-activated protein kinase (MAPK) altered colon and thyroid cancer models.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers demonstrated that the multispecificity BET/EP300 inhibitor XP-524 has pronounced single-agent efficacy in vitro, in vivo, and ex vivo human PDAC slice cultures, functioning in part by attenuating oncogenic KRAS signaling.

[International Journal of Biological Macromolecules] Researchers investigated systematically the roles of a proteoglycan from Ganoderma lucidum in protection and repair of pancreatic β-cells against oxidative stress-induced injury and apoptosis on molecular, cellular and animal basis.

[Cancer Immunology Immunotherapy] Scientists investigated in vitro, ex vivo and in vivo effects of a novel chemical compound targeting HCK inhibition, in combination with the most used drugs for the treatment of myelodysplastic syndrome and de novo acute myeloid leukemia, 5-Azacytidine and Cytarabine.

[Cell Death & Disease] The authors showed 2nd generation hexameric TRAIL-receptor-agonist IZI1551 to effectively induce apoptosis in malignant melanoma cells irrespective of the intrinsic BRAF/NRAS mutation status.

[Cell Death Discovery] Scientists revealed that endometrial stromal cell ferroptosis in the ovarian endometrioma may have triggered cytokine secretion and promoted angiogenesis of adjacent lesions via paracrine actions to drive the development of endometriosis.